Characteristic | All Patients (n = 16) | Placebo (n = 10) | Testosterone (n = 6) | P = value |
---|---|---|---|---|
Time (mos) from diagnosis to enrollment – mean (SD) | 3.1 (3.2) | 2.9 (3.4) | 3.6 (3.1) | 0.684 |
Age (yrs) – mean (SD) | 50.9 (9.5) | 48.4 (10.9) | 55.0 (5.1) | 0.189 |
BMI (kg/m2) – mean (SD) | 22.1 (6.8) | 23.9 (7.3) | 19.3 (5.2) | 0.200 |
aExercise behavior (activity score) – mean (SD) | 9.0 (8.0) | 9.9 (9.6) | 7.1 (3.6) | 0.588 |
Race – no. (%) |  |  |  | 0.330 |
 Non-Hispanic white | 11 (69) | 6 (60) | 5 (83) |  |
 Other group | 5 (31) | 4 (40) | 1 (20) |  |
Sex – no. (%) |  |  |  | 0.091 |
 Male | 7 (44) | 6 (60) | 1 (17) |  |
 Female | 9 (56) | 4 (40) | 5 (83) |  |
Smoking – no. (%) | n = 16 | n = 10 | n = 6 | 0.355 |
 Never | 4 (25) | 3 (30) | 1 (17) |  |
 Former | 7 (44) | 3 (330) | 4 (67) |  |
 Current | 5 (31) | 4 (40) | 1 (17) |  |
Disease stage – no. (%) | n = 15 | n = 9 | n = 6 | 0.852 |
 IIB | 1 (7) | 0 (0) | 1 (17) |  |
 III | 0 (0) | 0 (0) | 0 (0) |  |
 IIIB | 4 (27) | 3 (33) | 1 (17) |  |
 IV | 0 (0) | 0 (0) | 0 (0) |  |
 IVA | 8 (53) | 5 (56) | 3 (50) |  |
 IVB | 2 (13) | 1 (11) | 1 (17) |  |
Cancer Type – no. (%) |  |  |  | 1.000 |
 Cervical | 6 (38) | 4 (40) | 2 (33) |  |
 Head/neck | 10 (62) | 6 (60) | 4 (37) |  |
PEG feeding tube – no. (%) | 6 (38) | 3 (30) | 3 (50) | 0.986 |
Current Therapy – no. (%) | ||||
 Chemotherapy | 11 (69) | 6 (60) | 5 (83) | 0.985 |
 Radiotherapy | 13 (81) | 9 (90) | 4 (67) |  |
 Other Therapy | 0 (0) | 0 (0) | 0 (0) |  |
Prior therapy – no. (%) | n = 16 | n = 10 | n = 6 | 0.927 |
 Surgery | 2 (13) | 2 (20) | 0 (0) |  |
 Chemotherapy | 0 (0) | 0 (0) | 0 (0) |  |
 Radiotherapy | 0 (0) | 0 (0) | 0 (0) |  |
 Other Therapy | 0 (0) | 0 (0) | 0 (0) |  |
Current Medications – no. (%) | n = 16 | n = 10 | n = 6 | 0.728 |
 Beta-blocker | 0 (0) | 0 (0) | 0 (0) |  |
 ACE inhibitor | 1 (6) | 1 (10) | 0 (0) |  |
 ARB | 1 (6) | 1 (10) | 0 (0) |  |
 Diuretic | 1 (6) | 1 (10) | 0 (0) |  |
 Calcium channel blocker | 1 (6) | 1 (10) | 0 (0) |  |
 Aspirin | 3 (19) | 2 (20) | 1 (17) |  |
 Statin | 2 (13) | 2 (20) | 0 (0) |  |
Pre-existing conditions – no. (%) | n = 16 | n = 10 | n = 6 | 0.586 |
 Peripheral vascular disease | 2 (13) | 1 (10) | 1 (17) |  |
 Coronary artery disease | 1 (6) | 1 (10) | 0 (0) |  |
 Osteoporosis | 1 (6) | 0 (0) | 1 (17) |  |
 Arrhythmia | 0 (0) | 0 (0) | 0 (0) |  |
 Arthritis | 0 (0) | 0 (0) | 0 (0) |  |
 Type II diabetes | 2 (13) | 2 (20) | 0 (0) |  |
 Hyperlipidemia | 2 (13) | 2 (20) | 0 (0) |  |
 Hypertension | 1 (6) | 1 (10) | 0 (0) |  |